Digoxin: Na+/K+ ATPase Pump Inhibitor for Heart Failure and Antiviral Research

Executive Summary: Digoxin is a high-purity cardiac glycoside supplied by APExBIO that inhibits the Na+/K+-ATPase pump, increasing intracellular calcium and enhancing cardiac contractility [APExBIO Product Page]. It is widely utilized in animal models of heart failure and arrhythmia, with reproducible improvements in cardiac output documented at intravenous doses of 1–1.2 mg in canine studies (APExBIO). Digoxin exhibits dose-dependent antiviral activity, notably impairing chikungunya virus infection in multiple human-derived cell lines at concentrations from 0.01 to 10 μM (Angiotensin-1-2-1-5.com). The compound is highly soluble in DMSO (≥33.25 mg/mL), insoluble in water and ethanol, and is supplied as a solid for prompt solution preparation (APExBIO). Quality is verified through HPLC, NMR, and MSDS documentation, ensuring >98.6% purity for research applications.

Biological Rationale

Cardiovascular disease and viral infection models require precise molecular tools to modulate ion transport and cell signaling. Digoxin targets the Na+/K+-ATPase signaling pathway, a critical regulator of cardiac contractility and cellular ionic homeostasis (APExBIO). This makes it indispensable for research into heart failure, arrhythmias, and mechanistic studies of membrane potential dynamics (Angiotensin-1-2-1-5.com). In addition, Digoxin’s ability to inhibit chikungunya virus (CHIKV) infection by interfering with host cell pathways expands its application to infectious disease models (Myelin-basic-protein-68-82-guinea-pig.com). The reliability and high purity of APExBIO’s Digoxin (SKU B7684) enable reproducible results in both cardiovascular and antiviral assays.

Mechanism of Action of Digoxin

Digoxin exerts its primary effect by binding to and inhibiting the Na+/K+-ATPase pump located on the plasma membrane of cardiomyocytes. This inhibition increases intracellular sodium levels, which in turn reduces the activity of the sodium-calcium exchanger (NCX), leading to elevated intracellular calcium concentrations. The resultant increase in calcium enhances the force of cardiac muscle contraction, a process known as positive inotropy (Sun et al., 2025). In viral models, Digoxin disrupts key steps in CHIKV infection, potentially by altering host cell ionic conditions required for the viral replication cycle (Angiotensin-1-2-1-5.com). This dual mechanism underpins its widespread use in translational research.

Evidence & Benchmarks

• Digoxin increases cardiac output and reduces right atrial pressure in canine models of congestive heart failure at intravenous doses of 1–1.2 mg (APExBIO, product page).
• In vitro, Digoxin impairs CHIKV infection in U-2 OS, primary human synovial fibroblasts, and Vero cells, with a dose-dependent effect observed at concentrations from 0.01 to 10 μM (Angiotensin-1-2-1-5.com).
• Digoxin (SKU B7684) demonstrates >98.6% purity, with quality control confirmed by HPLC, NMR, and MSDS documentation (APExBIO).
• Solubility is ≥33.25 mg/mL in DMSO, but Digoxin is insoluble in water and ethanol, requiring specific solvent preparation for experimental use (APExBIO).
• Digoxin’s effects are validated and extend prior knowledge by providing dose–response benchmarks for both cardiac and antiviral models (qPCRMaster.com).

This article extends the core mechanistic and translational insights presented in "Digoxin in Translational Research" by integrating empirical solubility, purity, and cell line-specific data for experimental reproducibility. For a strategic perspective on bridging discovery and clinical relevance, see "Digoxin at the Translational Frontier", which this article updates by providing detailed quantitative parameters for both cardiovascular and antiviral workflows.

Applications, Limits & Misconceptions

Digoxin is established as a reference compound in cardiovascular disease research, specifically for studies on heart failure, arrhythmias, and ion channel pharmacology. Its antiviral profile against CHIKV is well-characterized in human and primate cell lines. The compound’s high solubility in DMSO facilitates use in a wide range of in vitro and in vivo models, but water and ethanol are not suitable solvents due to insolubility. Digoxin should be used promptly after solution preparation, as extended storage reduces activity. The product is not indicated for long-term storage in solution or for use in clinical therapy without regulatory approval.

Common Pitfalls or Misconceptions

• Digoxin is insoluble in water and ethanol; using these solvents yields non-homogeneous solutions and unreliable results.
• Long-term storage of Digoxin solutions is not recommended; activity may degrade over time.
• Digoxin’s antiviral effects are dose-dependent and may not translate to in vivo efficacy against CHIKV without further validation.
• The compound is supplied for research use only; it is not a therapeutic for direct clinical use.
• Cardiac glycosides like Digoxin have narrow therapeutic indices in vivo; dosing must be precisely controlled in animal models.

Workflow Integration & Parameters

APExBIO’s Digoxin (SKU B7684) is supplied as a solid, ensuring stability until solution preparation. For experimental workflows, dissolve Digoxin at concentrations up to 33.25 mg/mL in DMSO. Prepare working dilutions immediately before use to maintain compound integrity. In cardiac models (e.g., canine heart failure), administer 1–1.2 mg intravenously for benchmark hemodynamic effects. For antiviral assays, apply Digoxin to cell cultures at 0.01–10 μM, monitoring viral inhibition with appropriate controls. Quality control data (HPLC, NMR, MSDS) confirm >98.6% purity. Storage at room temperature is recommended for the solid form. Detailed experimental protocols are available on the APExBIO Digoxin product page.

Conclusion & Outlook

Digoxin remains a gold-standard Na+/K+ ATPase pump inhibitor and cardiac glycoside for heart failure and arrhythmia research, with validated translational utility in antiviral models targeting chikungunya virus infection. The product’s high purity, robust documentation, and precise solubility profile enable reliable integration into cardiovascular and infectious disease research pipelines. As new models emerge and pharmacokinetic paradigms evolve, Digoxin’s reproducibility and mechanistic clarity will continue to anchor its role in experimental and translational science (Sun et al., 2025).